抄録
Effects of 12 weeks treatment with S, a bile acid sequestrant (C), B, or P were compared in 32, 16, 30, and 22 patients with hyperlipoproteinemia. Plasma levels of lipoprotein subfraction-cholesterol (C), and activities of LCAT and CETP were measured at 0 and 12 weeks. LDL receptor activities in lymphocytes cultured in lipoprotein-deficient medium were also assayed. S, B, and P reduced plasma levels of VLDL-C and IDL-C but C did not. S, C, and P reduced plasma levels of LDL1 (1.019<d<1.045)-C but B did not. S and B reduced plasma levels of LDL2 (1.045<d<1.063)-C but C and P did not change. P markedly reduced plasma levels of HDL2-C but S, C, and B did not change them. B increased plasma levels of HDL3-C and P decreased them. S and B decreased the cholesterol esterification rate but C and P did not change. P markedly increased CETP activities and S and B decreased them. LDL receptor activities positively correlated with the druginduced reduction of LDL-C and LDL1-C.
We conclude that the reduction of plasma lev ls of large, light LDL by drug treatment is mainly regulated by LDL receptor activities and the reduction of LDLi by drug treatment is more prominent in patients with lower LDL receptor activities.
